Egr-ly awaiting a "personalized medicine" approach to treat scleroderma

Journal of Cell Communication and Signaling

Volumn 6, Issue 2, 2012, Pages 111-113

  Leask, Andrew ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Egr 1; Fibrosis; Graft versus host; IL 13; Scleroderma

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; INTERLEUKIN 13; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; FIBROSIS; GENE OVEREXPRESSION; GRAFT VERSUS HOST REACTION; HUMAN; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SCLERODERMA; SIGNAL TRANSDUCTION;

MURINAE;

EID: 84863093906     PISSN: 18739601     EISSN: 1873961X     Source Type: Journal    
DOI: 10.1007/s12079-012-0160-8     Document Type: Article

References (17)

1. Abraham DJ, Krieg T, Distler J, Distler O (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 48(Suppl 3):iii3-iii7
2. Bhattacharyya S, Wu M, Fang F, Tourtellotte W, Feghali-Bostwick C, Varga J (2011a) Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy. Matrix Biol 30:235-242
3. Bhattacharyya S, Sargent JL, Du P, Lin S, Tourtellotte WG, Takehara K, Whitfield ML, Varga J (2011b) Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. PLoS One 6:e23082
4. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen F, Herrick A, Mayes MD, Veale D, Haas J, Ledbetter S, Korn JH, Black CM, Seibold JR, Cat-192 Study Group, Scleroderma Clinical Trials Consortium (2007) Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 56:323-333 (Pubitemid 46106206)
5. Fleming JN, Shulman HM, Nash RA, Johnson PY, Wight TN, Gown A, Schwartz SM (2009) Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis. PLoS One 4:e6203
6. Giordano N, Puccetti L, Papakostas P, Di Pietra N, Bruni F, Pasqui AL, Acampa M, Bocchi V, Donati V, Voglino M, Fioravanti A, Montella A, Auteri A, Nuti R, Pastorelli M (2010) Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study. Int J Immunopathol Pharmacol 23:1185-1194
7. Greenblatt MB, Sargent JL, Farina G, Tsang K, Lafyatis R, Glimcher LH, Whitfield ML, Aliprantis AO (2012) Interspecies Comparison of Human and Murine Scleroderma Reveals IL-13 and CCL2 as Disease Subset-Specific Targets. Am J Pathol. doi:10.1016/j.ajpath.2011.11.024
8. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A (2001) CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 276:10594-10601 (Pubitemid 38089227)
9. Ishida W, Mori Y, Lakos G, Sun L, Shan F, Bowes S, Josiah S, Lee WC, Singh J, Ling LE, Varga J (2006) Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. J Invest Dermatol 126:1733-1744 (Pubitemid 44086506)
10. Leask A (2008) Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell Signal 20:1409-1414
11. LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573-1576 (Pubitemid 32660630)
12. Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, Whitfield ML (2008) Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 3: e2696
13. Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, Chang HY, Whitfield ML (2010) ATGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 130:694-705
14. Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, Matucci Cerinic M, Riemekasten G, Emery P, Chadha-Boreham H, Charef P, Roux S, Black CM (2010) Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 62:2101-2108
15. Simms RW, Lafyatis R (2010) Rituximab: a potential therapeutic advance in scleroderma: what is the evidence? Rheumatology (Oxford) 49(2):201-202
16. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 100:12319-12324 (Pubitemid 37271558)
17. Zulian F (2008) New developments in localized scleroderma. Curr Opin Rheumatol 20:601-607